Capsida Biotherapeutics Inc. is a fully integrated biotechnology company creating a new class of targeted adeno-associated virus (AAV) gene therapies for patients with debilitating and life-threatening genetic disorders.
The company engaged FPBA to design a new cGMP manufacturing facility for production of AAV gene therapies.
The facility includes two ballroom production suites, a fill suite, and an in-house quality-control laboratory. Single-use bioreactors provide efficient product changeovers and equipment cleaning.
“The fact that we were able to go from detailed design to mechanical completion in less than a year is incredible,” said Rob Murphy, vice president of manufacturing at Capsida.
“The faster we are able to produce clinical supplies, the faster we’ll be able to get our innovative gene therapies to the patients who need them. This was all made possible by our fantastic team and our terrific partners.”